Key Market Overview:
Biosimulation Market size was worth USD 2.5 Billion in 2022, accounting for a CAGR of 16.8% during the forecast period (2023-2030), and the market is projected to be worth USD 10.1 Billion by 2030.
Biosimulation is a computational approach to understanding biological systems and processes by using mathematical models to simulate and predict their behavior. It involves the use of computer programs to integrate and analyze experimental data from various sources, such as genomics, proteomics, and metabolomics, to build and validate models of complex biological systems. These models are used to simulate the behavior of living organisms at different levels of an organization, from the molecular and cellular to the organismal and population levels.
Biosimulation has a wide range of applications in many areas of biology and medicine, such as drug discovery, toxicology, and personalized medicine. By simulating the effects of different drugs or interventions on biological systems, biosimulation helps researchers identify potential drug targets and optimize dosing regimens for individual patients. This is also used to predict the long-term effects of environmental exposures or disease on biological systems, which helps to inform public health policies and interventions.
The biosimulation market is primarily driven by the growing demand for effective and efficient drug discovery and development processes. The high failure rate and cost associated with traditional drug development methods have prompted pharmaceutical companies to adopt biosimulation tools and technologies as a means of reducing risk, improving success rates, and lowering costs. Additionally, the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, has created a need for personalized medicine approaches.
For instance, according to WHO, cancer is one of the leading causes of death worldwide, with an estimated 10 million cancer-related deaths in 2020 alone. The development of new cancer treatments is essential to reduce this number and improve patient outcomes. However, the process of developing and testing new cancer treatments is lengthy and expensive, with a high failure rate. As a result, biosimulation helps to accelerate the drug development process by allowing researchers to simulate the effects of new treatments in a virtual environment. This enables them to identify potential issues and optimize the treatment before proceeding to clinical trials, which saves both time and money.
Furthermore, biosimulation is well-suited for personalized medicine as it allows for the simulation of drug efficacy and safety in individual patients, based on their unique biological characteristics. Therefore, the above-mentioned factors propel the market growth.
Biosimulation requires advanced computational tools and data analytics expertise, which is expensive to develop and maintain. This limits the adoption of biosimulation, particularly among small and mid-sized pharmaceutical companies and research institutions. Also, biosimulation models require large amounts of high-quality data from multiple sources, such as genomics, proteomics, and metabolomics. Thus, the aforementioned factors hamper the market growth.
The biosimulation market presents a significant business opportunity, as artificial intelligence and machine learning technologies provide meaningful insights earlier in the drug development process with unprecedented accuracy and scalability. By leveraging biosimulation, companies de-risk R&D decisions and reduce the need for costly and time-consuming animal testing, which has a low success rate and raises ethical concerns. AI-powered biosimulation enables the creation of computer models that simulate the behavior of biological systems, allowing companies to understand multiple interdependencies and scenarios simultaneously. This helps to accelerate drug development timelines and increase translatability, ultimately improving the chances of success and reducing costs.
Biosimulation Report Coverage:
|Report Attributes||Report Details|
|Market Size in 2030 (USD Billion)||10.1 Billion|
|By Component||Software and Services (In-House Services and Contract Services)|
|By Deployment||Subscription Models and Ownership Models|
|By Application||Drug Development, Drug Discovery, and Others|
|By End-use||Pharmaceutical & Biotechnology Companies, Academic Research Institutions, CROs, and Others|
|By Region||North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa|
|Key Players||Certara, L.P., Simulations Plus, Inc., Dassault Systèmes SE, Exploristics Ltd, Applied BioMath, LLC, Chemical Computing Group ULC, Physiomics Plc, BioSimulation Consulting Inc., Immunetrics Inc., and Genedata AG|
Based on components, the biosimulation market is classified into software and services. The software segment holds the largest market share in the year 2022. This is attributed to the pharmacokinetic and pharmacodynamic (PK/PD) modeling software. Pharmacokinetic and pharmacodynamic (PK-PD) modeling is a valuable tool in improving our understanding of the in vivo behavior of complex drug delivery systems and facilitating their development. This modeling approach enables the separation of the drug-specific, carrier-specific, and pharmacological system-specific parameters, which can help to identify key factors affecting the delivery and efficacy of the drug. As a result, PK-PD modeling has been widely used in drug development to optimize drug delivery systems and improve therapeutic outcomes.
However, the services segment of the biosimulation market is expected to be the fastest growing segment over the forecast period. This is due to the growing demand for biosimulation services, such as systems pharmacology and quantitative systems pharmacology (QSP).
Based on deployment, the market is categorized into subscription models and ownership models. The subscription model holds the largest market share in the year 2022. A subscription model typically refers to a pricing model where customers pay a recurring fee to access software, data, and/or services offered by biosimulation companies. The customers access the software and data remotely and pay a monthly or yearly subscription fee for continued access. This model is advantageous for customers as it allows for predictable costs and flexibility in terms of usage, while also providing recurring revenue streams for biosimulation companies.
However, the ownership model is expected to witness fastest CAGR over the forecast period. This model is advantageous for customers who require more control over the software or data, and may not want to rely on cloud-based solutions. For biosimulation companies, this model provides a larger upfront revenue stream.
Based on application, the market is categorized into drug development, drug discovery, and others. The drug development segment holds the largest market share in the year 2022. This is due to the increasing need for pharmaceutical and biotech companies to optimize the drug development process, and biosimulation provides a cost-effective and efficient way to do this. Biosimulation helps companies to better understand drug metabolism, pharmacokinetics, and pharmacodynamics, which can ultimately lead to faster and more effective drug development.
However, the drug discovery segment is the fastest-growing application segment within the biosimulation market. As biosimulation helps researchers to identify promising drug candidates more quickly and to reduce the number of costly and time-consuming experiments required to bring a drug to market.
Based on the end-use segment the market is classified into pharmaceutical & biotechnology companies, academic research institutions, CROs, and others. The pharmaceutical and biotechnology companies hold the largest market share in the year 2022. This is due to the increasing need for these companies to optimize the drug discovery and development process, and biosimulation offers a cost-effective and efficient way to do this. Biosimulation helps these companies to better understand drug metabolism, pharmacokinetics, and pharmacodynamics, which ultimately leads to faster and more effective drug development.
However, CROs (Contract Research Organizations) are expected to witness the fastest-growing CAGR over the forecast period. As they are increasingly using biosimulation to help streamline their drug development processes. Biosimulation can help CROs to better understand drug efficacy and toxicity, which ultimately lead to more efficient clinical trials.
Based on region, the Biosimulation market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest market share in the year 2022. This is due to the presence of several leading pharmaceutical and biotechnology companies in the region such as Certara, L.P. The region also has a well-established healthcare infrastructure and a favorable regulatory environment for biosimulation. The United States is the largest market in the region, accounting for a significant share of the global market.
Furthermore, Asia-Pacific is expected to witness the fastest growth in the biosimulation market, owing to the increasing demand for effective and affordable healthcare solutions, rising investments in R&D, and growing awareness about the benefits of biosimulation. Japan, China, India, and South Korea are among the key markets in the region.
Biosimulation Market Competitive Landscape:
The market is highly competitive, with a large number of players operating at the global and regional levels. The players compete on various parameters such as price, quality, innovation, and customer service. They are constantly investing in research and development to improve their products and expand their market share. Mergers, acquisitions, and partnerships are also common strategies employed by companies to enhance their market position and expand their product portfolio. Key players in the market include-
- Certara, L.P.
- Simulations Plus, Inc.
- Dassault Systèmes SE
- Exploristics Ltd
- Applied BioMath, LLC
- Chemical Computing Group ULC
- Physiomics Plc
- BioSimulation Consulting Inc.
- Immunetrics Inc
- Genedata AG
- In June 2022, Certara, a leading biosimulation company launched the updated versions of its Immunogenicity (IG), Immuno-Oncology (IO), and Vaccine Simulators. These tools enable drug developers to predict how drugs work and answer critical questions in the development of biological therapies. This launch is expected to provide Certara with a competitive edge in the biosimulation market by offering more accurate and reliable predictions, ultimately improving the success rates of drug development programs.
- In April 2021, Applied BioMath, a biosimulation software company, has launched its first software solution, Applied BioMath Assess. This solution assists project leaders and protein engineers in assessing the challenges they encounter during the development of biotherapeutics. The launch of Applied BioMath Assess is expected to strengthen Applied BioMath’s position in the biosimulation market by providing a unique and efficient solution to a critical challenge faced by drug developers, ultimately improving the efficiency and success rates of drug development programs.
Table of Content
To check our Table of Contents, please mail us at: [email protected]
Research MethodologyThe Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.
Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.